Category

Uncategorized
Doylestown, PA Nov. 5th 2019/– Diverse Biotech, Inc. has announced it has successfully synthesized its first three new chemical entities (NCEs) and have progressed them into the pre-clinical testing starting with in vitro testing. These NCEs will be targeting basal cell carcinoma, pancreatic cancer, and glioblastoma with the ultimate future goal of establishing new standards...
Read More
Doylestown, PA Nov. 1st 2019/– Diverse Biotech, Inc. has announced it has opened its Headquarters at the Pennsylvania Biotechnology Center which is a prominent incubator for small growing life sciences companies in Doylestown, PA. The PA Biotechnology Center contains a wealth of resources and a core support group of scientists and executives motivated to work...
Read More

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Our Cases

Tag Cloud